Ligand Pharmaceuticals Inc
LGND· Nasdaq
LGNDLigand Pharmaceuticals Inc
Filed Feb 27, 2026 · 10-K · 58 days after period end · 0000886163-26-000006
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 |
|---|---|---|---|---|
| Revenue | $59.67M | $42.81M | $28.10M | $50.38M |
| Net Income | $44.78M | -$31.09M | $18.19M | -$17.49M |
| EPS Diluted | — | — |
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
| — |
| -$0.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Feb 27, 2026 · 58 d after period end
